ITRM
Income statement / Annual
Last year (2024), Iterum Therapeutics plc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Iterum Therapeutics plc's net income was -$24.77 M.
See Iterum Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$37.00 K |
$869.00 K |
$508.00 K |
$0.00 |
| Cost of Revenue |
$254.00 K
|
$1.75 M
|
$1.80 M
|
$2.10 M
|
$161.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$254.00 K
|
-$1.75 M
|
-$1.80 M
|
-$2.10 M
|
-$161.00 K
|
$37.00 K
|
$869.00 K
|
$508.00 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$10.46 M
|
$38.24 M
|
$15.82 M
|
$8.61 M
|
$20.91 M
|
$90.77 M
|
$68.65 M
|
$25.50 M
|
$10.10 M
|
| General & Administrative Expenses |
$7.98 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.28 M
|
$8.78 M
|
$4.46 M
|
$3.26 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.98 M
|
$7.48 M
|
$12.77 M
|
$13.83 M
|
$11.05 M
|
$11.28 M
|
$8.78 M
|
$4.46 M
|
$3.26 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$196.00 K
|
$401.00 K
|
$0.00
|
$8.00 K
|
| Operating Expenses |
$18.44 M
|
$45.72 M
|
$28.58 M
|
$22.43 M
|
$31.97 M
|
$102.06 M
|
$77.43 M
|
$29.96 M
|
$13.36 M
|
| Cost And Expenses |
$18.70 M
|
$47.47 M
|
$30.38 M
|
$24.54 M
|
$32.13 M
|
$102.06 M
|
$77.43 M
|
$29.96 M
|
$13.36 M
|
| Interest Income |
$0.00
|
$1.43 M
|
$2.36 K
|
$4.53 K
|
$12.30 K
|
$0.00
|
$0.00
|
$277.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$2.36 M
|
$5.55 M
|
$15.10 M
|
$861.00 K
|
$426.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$284.00 K
|
$1.75 M
|
$1.80 M
|
$2.10 M
|
$161.00 K
|
$152.00 K
|
$136.00 K
|
$65.00 K
|
$13.36 M
|
| EBITDA |
-$21.73 M |
-$34.58 M |
-$39.97 M |
-$83.20 M |
-$36.01 M |
-$101.67 M |
-$76.02 M |
-$29.39 M |
-$13.35 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-2747.92
|
-87.48
|
-57.85
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-2757.32
|
-88.1
|
-57.98
|
0
|
| Total Other Income/Expenses Net |
-$5.84 M
|
$9.71 M
|
-$13.75 M
|
-$66.32 M
|
-$19.14 M
|
-$665.00 K
|
-$25.00 K
|
$493.00 K
|
$8.00 K
|
| Income Before Tax |
-$24.53 M
|
-$37.76 M
|
-$44.13 M
|
-$90.86 M
|
-$51.26 M
|
-$102.69 M
|
-$76.58 M
|
-$28.96 M
|
-$13.35 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-2775.3
|
-88.13
|
-57.01
|
0
|
| Income Tax Expense |
$240.00 K
|
$613.00 K
|
$301.00 K
|
$705.00 K
|
$743.00 K
|
$444.00 K
|
$472.00 K
|
$444.00 K
|
$113.00 K
|
| Net Income |
-$24.77 M
|
-$38.37 M
|
-$44.43 M
|
-$91.56 M
|
-$52.01 M
|
-$103.13 M
|
-$77.06 M
|
-$29.41 M
|
-$13.46 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-2787.3
|
-88.67
|
-57.89
|
0
|
| EPS |
-1.26 |
-2.96 |
-3.63 |
-8.41 |
-32.49 |
-7.1 |
-98.32 |
-58.08 |
-26.59 |
| EPS Diluted |
-1.26 |
-2.96 |
-3.63 |
-8.41 |
-32.49 |
-7.1 |
-98.32 |
-58.08 |
-26.59 |
| Weighted Average Shares Out |
$19.70 M
|
$12.96 M
|
$12.24 M
|
$10.89 M
|
$24.01 M
|
$1.05 M
|
$631.57 K
|
$549.15 K
|
$13.96 M
|
| Weighted Average Shares Out Diluted |
$19.70 M
|
$12.96 M
|
$12.24 M
|
$10.89 M
|
$24.01 M
|
$1.05 M
|
$631.57 K
|
$549.15 K
|
$13.96 M
|
| Link |
|
|
|
|
|
|
|
|
|
